day after first semaglutide injection Week 1 on Semaglutide: Experience Your First 30 Days on

This systematic review evaluates the efficacy, tolerability, and neurobiological rationale of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonists in treating nicotine use disorder (NUD), with particular attention to smoking abstinence, craving reduction, weight gain mitigation, and mechanistic insights

Learn when it's safe to start GLP-1 after pregnancy, breastfeeding considerations, eligibility, benefits, risks, and expert postpartum weight loss tips.

Explore weight management medications that support healthy goals.

al., 4:24-cv-0953-P, slip op., 2025 WL 746028, at *15 (N.D

The bigger message is that these agents are pushing us toward a more integrated cardiometabolic model of care, in which obesity, heart failure, kidney disease, liver disease, and vascular risk are treated as connected biology rather than asseparate silos.